Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
RefCam2
how dumb and bad at math people are..... Hilarious!
-- The calculation for allocation of post reverse split shares is to be effectuated based on Shareholders of record as of March 30, 2020.
Just placed my sell order. Better to take the loss now.
Looks like SKDI has some new pumpers in here. Must be running low on cash.
Has anyone reached out to IR/Hank recently? I tried twice at the end of April about updates and he has yet to reply. In the past he’s been pretty good with responding. Maybe he bailed too.
None.
I guessing a RS in the near future
I hope everyone read your post. I expect a rise followed by a huge fall. I plan on staying for the long. Good luck everyone!
well im just the dude replying to the dude standing up for the dude. LOL
That "dude" is Investor Relations. You know , that guy who responds to the thousands of emails he gets everyday. He is not management. Id say he is entitled to a break.
okay so i don't post much but i just have to say some of you are hilarious! You half ass read something from a post or dont do your own DD and then come on here and post something on here not having a clue what you are talking about. I'm guessing by the lack of knowledge being shown you are probably quite deep in the red. Why even post on here if you have such negativity towards this stock. I think you guys should consider to quit trading while you have a chance and go back to your pull tabs.
how is it with all the buys going on is this not moving up?
Maybe you should ask them. info@dnadynamicsinc.com
i agree with you. Unless something happens before then I will be selling right after RS. After that I will probably short it.
VANCOUVER, Sept. 12, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the holders ("Holders") of its senior secured convertible notes (the "Notes") have agreed to amend certain terms of the Notes and other concessions, including a one-year extension of the maturity of the Notes from May 17, 2019 until May 17, 2020.
"We have negotiated with the debt note-holders and, though we have little to no leverage, convinced them to give us some concessions, for which we are grateful. Most importantly, the extension of the expiration date for the convertible debt by one year will provide the Company with greater flexibility for repayment of the debt, and while no predictions can be made as to conversions, this extension may ease the pressure on the conversions," commented Fred Colen, Neovasc's President and Chief Executive Officer.
The Company has entered into a Waiver Agreement applicable to the Holders of all of the Notes, pursuant to which (1) the maturity date of the Notes is extended by one year from May 17, 2019 until May 17, 2020, (2) the Company's permitted quarterly Cash Burn (as defined in the Notes) is increased for certain future periods, (3) certain asset allowances applicable to the Company's subsidiaries are increased, and (4) issuances of the Company's common shares (the "Common Shares") that would qualify as Excluded Securities (as defined in the Notes) and not a Dilutive Issuance (as defined in the Notes) but for the fact that such issuances exceed 10% of the issued and outstanding Common Shares, will not be considered a Dilutive Issuance, provided that such Common Shares do not exceed 15% of the issued and outstanding Common Shares.
Concurrent with the Waiver Agreement, the Company entered into Lockup and Leak-Out Agreements applicable to the Holders of all of the Notes pursuant to which the Holders have agreed (1) not to sell Common Shares during the 5 consecutive trading days preceding and 15 consecutive trading days following execution of the Company's planned reverse stock split (the "Lockup"), which was announced yesterday and (2) that on any trading day from the expiration of the Lockup until November 30, 2018, they will not sell Common Shares in an amount exceeding 15% of the daily average composite trading volume of the Common Shares on such trading day (the "Leak-Out"). Both the Lockup and the Leak-Out are subject to an exception allowing Holders to sell Common Shares of the Company if such sales occur at a price equal to or in excess of the lower of (a) 150% of the Alternate Conversion Price (as defined in the Notes) and (b) US$0.0365 (or US$3.65 following the reverse stock split).
ME: Will there be any updates this quarter? I understand the process is time consuming but can you give any type of timetable or any info on the current position of testing for the IND application? Any information on the August 30th contract deadline? Any info would help. Thanks!
IR: Thank you for contacting PharmaCyte Biotech. At the present time, we have no plans for a lengthy and time-consuming type of update that we have conducted previously due to our limited personnel resources and our complete commitment towards preparing for the clinical trial in pancreatic cancer. Rather, we plan to keep our investors informed of progress through the use of Press Releases (a new one can be expected quite soon). In case you were unaware, all of our Press Releases can be found on our website by clicking on the “Investors” tab and then on the “News/Events” tab below that.
I reached out to IR to ask for an update of where PMCB is at with the trial and also the Aug 30th deadline and just got a reply. They basically said a new press release can be expected quite soon.
That's the one I am referring to. Thanks Bio! So you're saying there's a chance!
Now I could be wrong but, given I can’t find the post, but didn’t someone contact IR and the reply basically was not to expect news in third quarter?
For weeks now there is always someone on here every week posting they think there will be news this week. I wish it would be true but the fact is an IND filing won’t be till Nov/Dec at best. Going to be a good Xmas I hope!
Got it. Thanks!
How are where do you find that kind of information, seeing the trades and other peoples positions?
curious...what is your other biotech stock?